Clinical trial · Interventional
Argon Plasma Coagulation for Barrett's Esophagus
Argon Plasma Coagulation for Barrett's Esophagus With Low Grade Dysplasia: A Randomized Trial With Long Term Follow-up Evaluating the Impact of Power Setting and Proton Pump Inhibitor Dose
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Background and study aims. To evaluate the impact of power setting and proton pump inhibitor (PPI) dose on the efficacy and safety of argon plasma coagulation (APC) of Barrett's esophagus (BE) with low-grade dysplasia (LGD). Patients and methods. Investigator initiated, single-center, parallel-group randomized controlled trial (RCT) conducted in a tertiary referral center in Poland. Consecutive patients with BE and LGD were randomly assigned to APC with power set at 90 Watt (90W) or 60 Watt (60W) followed by 120 mg or 40 mg omeprazole for six weeks. The primary outcome of the study was the rate of complete (endoscopic and histologic) ablation of BE at six weeks. Secondary outcomes included safety and long-term efficacy (at two years and at the end of a long-term follow-up of over 4 years.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Barretts Esophagus With Low Grade Dysplasia | — | UNRESOLVED | — |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Argon Plasma Coagulation 60W power | Device | — | UNRESOLVED |
| Argon Plasma Coagulation 90W power | Device | — | UNRESOLVED |
| Omeprazole 120 mg | Drug | — | UNRESOLVED |
| Omeprazole 40 mg | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- APC 90W / PPI 120mg
- description
- treatment with high-power argon plasma coagulation (90 Watt) followed by acid suppression with high-dose oral omeprazole (40 mg t.i.d)
- interventionNames
- Device: Argon Plasma Coagulation 90W power
- Drug: Omeprazole 120 mg
- type
- ACTIVE_COMPARATOR
- label
- APC 90W / PPI 40mg
- description
- treatment with high-power argon plasma coagulation (90 Watt) followed by acid suppression with standard dose oral omeprazole (40 mg q.d)
- interventionNames
- Device: Argon Plasma Coagulation 90W power
- Drug: Omeprazole 40 mg
- type
- ACTIVE_COMPARATOR
- label
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * consecutive adult patients with low-grade dysplasia in flat Barrett's mucosa referred for endoscopic treatment, * signed an informed consent to participate in the study. Exclusion Criteria: * high-grade dysplasia or adenocarcinoma, * visible lesions (nodules, ulcerations) in Barrett's mucosa, * serious comorbidities and short life expectancy, * coagulopathy, * pregnancy or lactation, * psychiatric disorders.
References
Publications (1)
- DERIVEDWronska E, Polkowski M, Orlowska J, Mroz A, Wieszczy P, Regula J. Argon plasma coagulation for Barrett's esophagus with low-grade dysplasia: a randomized trial with long-term follow-up on the impact of power setting and proton pump inhibitor dose. Endoscopy. 2021 Feb;53(2):123-132. doi: 10.1055/a-1203-5930. Epub 2020 Jul 10. PMID 32650347